Established in 1982, Randox is dedicated to improving health worldwide by developing pioneering diagnostic technology.
Our Randox Health tests are available to purchase from www.randoxhealth.com As the largest healthcare diagnostics company from the UK and Ireland, Randox undertakes research, development, manufacture and distribution of innovative laboratory tests and equipment. In 2019 Randox, manufactured over 4 billion tests, and operated in 145 countries. With over 2,000 staff, including over 450 research scientists and engineers, key facilities are located in Co Antrim and Co Donegal. Randox focuses on the provision of comprehensive, accurate and timely testing in order to identify risk to health, improve clinical diagnoses and promote preventative healthcare; aiming to achieve better healthcare outcomes whilst reducing the burden on clinical services. In that regard Randox’s innovative Biochip Technology allows many tests to be run simultaneously, greatly improving the diagnostic power available to clinicians. These technologies enable Randox Health Clinics to provide public access to advanced health screening involving of hundreds of diagnostic tests. Such packages provide an extraordinary insight into a person’s current and future health. In early 2020 Randox recognised the threat from COVID-19 and, based on almost 40 years of diagnostic experience, quickly developed a test to accurately identify the virus. Testing at scale commenced within weeks to support both the UK’s National Testing Programme and testing for international travel. Through the enormous effort and commitment of their staff Randox has equipped over 80,000 sq ft of PCR testing facilities in Northern Ireland, Manchester and Greater London, as well as 50,000 sq ft of supporting logistics and engineering space. Randox has amongst the very largest laboratories in Europe, is the leading testing provider in the UK, and was the first to have reported over 100,000 PCR results in a single day. Randox is clear that better diagnostics are unquestionably critical to future improvements within healthcare, and is committed to remaining at the forefront of that field.
30/06/2025
Who says cake is only for weekends? Starting Monday right with a slice of sweet motivation 🍰✨This morning, our team celebrated our recent announcement that the U.S. Food and Drug Administration (FDA) has approved the De Novo application for our first Companion Diagnostic (CDx), bettering the lives of patients with hemophilia in collaboration with Novo Nordisk.
30/06/2025
Last week, Team China hosted it’s annual sales conference. The team grouped together to discuss the growth and future of diagnostics across the market.
Randox has operated in the market for almost 5 decades, providing quality and innovation with successful partnerships. We are excited for the future! 👏
27/06/2025
Where speed meets precision. Randox is proud to present Future Lab at the 2025 Goodwood Festival of Speed, running from 10th - 13th July.
Showcasing the answer to proactive and preventative healthcare, the Randox Biochip.
Rapid in technology, small in size, yet disruptive in impact!
Don’t miss this chance to witness the future of innovation at Goodwood!
20/06/2025
Our R&D team this weekend are excited to explore at the 85th American Diabetes Associaton, in Chicago.
Our teams focus, highlights the significant advancements Randox are achieving in unlocking the future of diabetes care.
02/06/2025
Randox Laboratories announced that the U.S. Food and Drug Administration (FDA) has approved the De Novo application for the company’s first Companion Diagnostic (CDx).
This is a major achievement for Randox following over 3 years of innovative development and collaboration with . The Companion Diagnostic was developed as a new option for determining the amount of medication a patient with hemophilia has received.
𝐑𝐚𝐧𝐝𝐨𝐱 𝐑𝐨𝐚𝐝𝐬𝐡𝐨𝐰𝐬 𝐂𝐡𝐢𝐧𝐚 𝟐𝟎𝟐𝟓. 3 weeks, multiple cities, collaborations and proud to supply!
Here are some of the highlights from our team who focused efforts on showcasing Randox’s capabilities in delivering smarter QC, for greater confidence in patient results.
21/05/2025
This week, we welcomed students from to the Randox Science Park as part of their spotlight on Life Sciences tour 2025. Students got to gain insights into manufacturing in diagnostics, engineering in life sciences and practical experiences within clinical laboratory settings.
15/05/2025
Where Prevention Meets Pawsitivity 🐾
This weekend, Randox Health celebrate proactive & preventive healthcare at the 2025 Goodwoof festival, 17th –18th May at the Goodwood Estate in West Sussex. 🌞
We look forward to welcoming all visitors to the Randox Health Studio, where we will be hosting a range of activities for you and your four-legged best friend! 🐩
14/05/2025
Balmoral Show 2025 🧑🌾
The Randox Health team are on home soil for the 156th edition of this annual spectacle.
📍 Stand A14, if you’re attending come have a chat with us!
24/04/2025
This week, we welcomed students to the Randox Science Park for our future scientists initiative. A day for sciences, skills and discovery collaboration and learning. 👏
Some of the highlights included an introduction to molecular and point of care, manufacturing, practical experience, careers in science and the future of the laboratory.
11/04/2025
We have arrived at this years ESCMID 2025!
Our team are looking forward to welcoming you all tomorrow on stand D60, to discuss our expertise in Molecular diagnostics and infectious disease testing!
13/12/2024
Transforming Bladder Cancer diagnosis with the Randox MultiSTAT🔎
Triaging patients with unexplained haematuria at primary care is a huge challenge. Current gold standard methods, such as cystoscopy, involve invasive investigations that can lead to further complications and infections, and in most cases prove to be unnecessary.
The Randox Bladder Cancer Biochip improves the likelihood of early detection with rapid results available in under 60 minutes. Requiring only a simple urine sample, the biochip helps to categorise patients into ‘high risk’ and ‘low risk’ groups for better patient management. With a high recurrence rate, the Randox Bladder Cancer biochip offers the ideal solution for simple and easy lifetime monitoring.
Be the first to know and let us send you an email when Randox posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.
That’s why for over 35 years Randox has been driving innovations in the crucial field of diagnostics, with the ambition of improving health worldwide.
Randox has a wide-range of divisions such as Quality Control, Reagents, Randox Toxicology, Randox Food Testing and Randox Clinical Laboratory Services (RCLS). This has positioned Randox as a global leader in the healthcare diagnostics industry: every year more than 5% of the world’s population receive a medical diagnosis using Randox products.
The company has over 1400 employees of 44 nationalities, including 400 scientists and engineers. These teams are engaged in pioneering research, developing innovative diagnostic tests and equipment to save and improve lives.
R&D is core to Randox’s philosophy, with up to 16% of turnover committed to R&D each year. Currently over 35 international collaborative projects are underway – and key collaborative partners include the Dana Ferber Cancer Institute, Transgene, and universities including Queen’s University Belfast and Ulster University.
Over 95% of its products are exported worldwide. They are used in hospitals, clinical and molecular laboratories, food testing, forensic toxicology, life sciences and veterinary laboratories. Randox has offices and distribution networks in over 145 countries and there are four key R&D and manufacturing sites in Co. Antrim, Northern Ireland; Donegal, Ireland; Bangalore, India; with a centre under development just outside Washington DC.
Randox’s plant in Dungloe has the potential to revolutionise the economy of West Donegal. Currently employing around 120 staff, this facility will expand to 540 by 2020, to include 180 research scientists and engineers. Randox Dungloe will expand as a world-leading diagnostic R&D, engineering and manufacturing site – providing exciting, highly-skilled employment opportunities within the region.
The company is also expanding its public-facing division – Randox Health. There are now clinics across the UK with new ones due to open in LA and Dubai. There is also a unique mobile service throughout the UK and Ireland. Using highly accurate and sensitive blood tests, Randox scientists assess whole body health with the aim of achieving early diagnosis and promoting an advanced, preventative approach to healthcare. Clients are then empowered to take action to prevent illness from developing and stay healthy for longer.
Randox has also become the first healthcare company to sponsor horse-racing, as a vehicle to promote the message of preventive health to a worldwide audience. It is the title sponsor of the world’s most popular jump race – the Randox Health Grand National – which commands an audience of more than 600 million people.
